PRAX
Praxis Precision Medicines, Inc.
Price Chart
Latest Quote
$282.31
+12.30 (+4.56%)
Current Price
| Previous Close | $270.01 |
| Open | $280.60 |
| Day High | $289.67 |
| Day Low | $274.16 |
| Volume | 698,565 |
Stock Information
| Shares Outstanding | 27.88M |
| Total Debt | $1.44M |
| Cash Equivalents | $786.87M |
| Net Income | $-326.53M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $7.87B |
| EPS (TTM) | $-13.41 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $7.09B |
| Income | $-326.53M |
| Book/sh | $50.61 |
| Cash/sh | $28.22 |
| Employees | 168 |
Financial Ratios
| Quick Ratio | 15.66 |
| Current Ratio | 15.88 |
| Debt/Eq | 0.10 |
Returns & Margins
| ROA | -23.04% |
| ROE | -35.32% |
Ownership
| Insider Ownership | 0.35% |
| Institutional Ownership | 116.80% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -27.73 |
| P/B | 5.58 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $617.67 |
Technical Indicators
| SMA20 | $291.41 |
| SMA50 | $316.03 |
| SMA200 | $245.31 |
| RSI | 33.99 |
| ATR | 22.9108 |
| Shares Float | 24.02M |
| Short Float | 13.13% |
| Short Ratio | 9.61 |
| Volatility | 2.75 |
| Rel Volume | 1.30 |
Performance History
| Week | +13.84% |
| Month | -11.95% |
| Quarter | -5.11% |
| 6 Months | +2.84% |
| YTD | -1.43% |
| Year | +549.59% |
| 3 Years | +1917.22% |
| 5 Years | -6.22% |
| 10 Years | -32.30% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $282.31 | 698,600 |
| 2026-06-17 | $270.01 | 473,500 |
| 2026-06-16 | $257.25 | 502,100 |
| 2026-06-15 | $264.54 | 544,200 |
| 2026-06-12 | $266.58 | 423,200 |
| 2026-06-11 | $247.98 | 428,900 |
| 2026-06-10 | $240.66 | 408,000 |
| 2026-06-09 | $250.33 | 465,500 |
| 2026-06-08 | $253.25 | 726,400 |
| 2026-06-05 | $254.00 | 617,700 |
| 2026-06-04 | $264.75 | 1,091,500 |
| 2026-06-03 | $278.93 | 676,500 |
| 2026-06-02 | $258.08 | 1,562,400 |
| 2026-06-01 | $335.16 | 290,900 |
| 2026-05-29 | $349.97 | 399,800 |
| 2026-05-28 | $352.63 | 222,600 |
| 2026-05-27 | $357.13 | 304,500 |
| 2026-05-26 | $350.60 | 384,700 |
| 2026-05-22 | $343.56 | 250,000 |
| 2026-05-21 | $350.56 | 286,300 |
| 2026-05-20 | $335.61 | 268,500 |
| 2026-05-19 | $320.61 | 300,500 |
About Praxis Precision Medicines, Inc.
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company's platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Solidus to discover and develop antisense oligonucleotide. It also develops ulixacaltamide, a small molecule inhibitor of T-type calcium channels that in NDA for the treatment of essential tremor; relutrigine, a small molecule, which is in NDA for the treatment of SCN2A- and SCN8A-developmental and epileptic encephalopathies (DEE), as well as in Phase 3 trial for broad DEEs; vormatrigine, a small molecule targeting the hyperexcitable state of sodium-channels in the brain that is in Phase 3 trial for the treatment of adjunctive focal epilepsy, as well as in Phase 2 trial for monotherapy focal epilepsy; and Elsunersen, a clinical-stage ASO designed to selectively decrease SCN2A gene expression, which is in Phase 3 trial for the treatment of SCN2A-DEE. In addition, the company is developing product candidates in pre-clinical trial comprising PRAX-020 to treat KCNT1; PRAX-080 that targets PCDH19 mosaic expression disorders; PRAX-090 for targeting SYNGAP1 loss-of-function; and PRAX-100 that targets SCN2A LoF mutations. It has a cooperation and license agreement with RogCon Inc.; and a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc. The company was formerly known as EpiPM Therapeutics, Inc. and changed its name to Praxis Precision Medicines, Inc. in October 2016. Praxis Precision Medicines, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.
đ° Latest News
Praxis Precision Medicines (PRAX) Stock After Mixed POWER1 Trial Results How Does The Valuation Stack Up
Simply Wall St. âĸ 2026-06-15T03:11:40Z
BTIG Reaffirms Buy Rating for Praxis Precision Medicines (PRAX)
Insider Monkey âĸ 2026-06-11T10:20:29Z
Praxis Precision Medicines (PRAX) Shares Phase 2/3 POWER1 Study Findings
Insider Monkey âĸ 2026-06-05T15:55:51Z
NewLimitâs $435M megaround; Lillyâs busy dealmaking week
BioPharma Dive âĸ 2026-06-03T11:15:00Z
Praxis Precision Medicines Faces Vormatrigine Setback And Reassesses Epilepsy Pipeline
Simply Wall St. âĸ 2026-06-03T05:13:40Z
Stock Indexes Post New Record Highs Amid AI Enthusiasm
Barchart âĸ 2026-06-02T20:32:34Z
The Shocking Twist That Sent This Seizure-Focused Biotech Into A Dive
Investor's Business Daily âĸ 2026-06-02T20:28:20Z
Sector Update: Healthcare Stocks Softer Late Afternoon
MT Newswires âĸ 2026-06-02T19:45:10ZStocks Push Higher on US Labor Market Strength and AI Spending
Barchart âĸ 2026-06-02T15:25:43Z
Stocks Pressured by Uncertainty of US-Iran Ceasefire Prospects
Barchart âĸ 2026-06-02T14:08:50Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $8,553,000 | $2,447,000 | $0 |
| Operating Revenue | $0 | $8,553,000 | $2,447,000 | $0 |
| Expenses | ||||
| Total Expenses | $326,198,000 | $208,718,000 | $128,820,000 | $214,986,000 |
| Other Income Expense | $22,930,000 | $17,346,000 | $3,096,000 | $957,000 |
| Other Non Operating Income Expenses | $22,930,000 | $17,346,000 | $3,096,000 | $957,000 |
| Operating Expense | $326,198,000 | $208,718,000 | $128,820,000 | $214,986,000 |
| General And Administrative Expense | $59,083,000 | $56,305,000 | $42,054,000 | $59,946,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-303,268,000 | $-182,819,000 | $-123,277,000 | $-214,029,000 |
| Normalized Income | $-303,268,000 | $-182,819,000 | $-123,277,000 | $-214,029,000 |
| Net Income From Continuing And Discontinued Operation | $-303,268,000 | $-182,819,000 | $-123,277,000 | $-214,029,000 |
| Total Operating Income As Reported | $-326,198,000 | $-200,165,000 | $-126,373,000 | $-214,986,000 |
| Net Income Common Stockholders | $-303,268,000 | $-182,819,000 | $-123,277,000 | $-214,029,000 |
| Net Income | $-303,268,000 | $-182,819,000 | $-123,277,000 | $-214,029,000 |
| Net Income Including Noncontrolling Interests | $-303,268,000 | $-182,819,000 | $-123,277,000 | $-214,029,000 |
| Net Income Continuous Operations | $-303,268,000 | $-182,819,000 | $-123,277,000 | $-214,029,000 |
| Pretax Income | $-303,268,000 | $-182,819,000 | $-123,277,000 | $-214,029,000 |
| Operating Income | $-326,198,000 | $-200,165,000 | $-126,373,000 | $-214,986,000 |
| Per Share | ||||
| Diluted EPS | $-13.48 | $-10.21 | $-18.69 | $-69.60 |
| Basic EPS | $-13.48 | $-10.21 | $-18.69 | $-69.60 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-326,058,000 | $-199,807,000 | $-125,941,000 | $-214,567,000 |
| Reconciled Depreciation | $140,000 | $358,000 | $432,000 | $419,000 |
| EBITDA (Bullshit earnings) | $-326,058,000 | $-199,807,000 | $-125,941,000 | $-214,567,000 |
| EBIT | $-326,198,000 | $-200,165,000 | $-126,373,000 | $-214,986,000 |
| Diluted Average Shares | $22,504,676 | $17,906,794 | $6,594,316 | $3,073,115 |
| Basic Average Shares | $22,504,676 | $17,906,794 | $6,594,316 | $3,073,115 |
| Diluted NI Availto Com Stockholders | $-303,268,000 | $-182,819,000 | $-123,277,000 | $-214,029,000 |
| Research And Development | $267,115,000 | $152,413,000 | $86,766,000 | $155,040,000 |
| Selling General And Administration | $59,083,000 | $56,305,000 | $42,054,000 | $59,946,000 |
| Other Gand A | $59,083,000 | $56,305,000 | $42,054,000 | $59,946,000 |
| Otherunder Preferred Stock Dividend | - | - | - | - |
| Tax Provision | - | - | - | - |
Fetched: 2026-06-15
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $878,136,000 | $445,450,000 | $69,669,000 | $76,106,000 |
| Total Assets | $937,907,000 | $483,110,000 | $87,948,000 | $115,128,000 |
| Total Non Current Assets | $326,996,000 | $78,738,000 | $3,068,000 | $4,288,000 |
| Investmentin Financial Assets | $326,757,000 | $76,961,000 | $0 | - |
| Current Assets | $610,911,000 | $404,372,000 | $84,880,000 | $110,840,000 |
| Other Current Assets | $11,580,000 | $11,805,000 | $3,580,000 | $10,351,000 |
| Cash Cash Equivalents And Short Term Investments | $599,331,000 | $392,567,000 | $81,300,000 | $100,489,000 |
| Cash And Cash Equivalents | $357,329,000 | $215,372,000 | $81,300,000 | $61,615,000 |
| Other Non Current Assets | - | $416,000 | $416,000 | $416,000 |
| Prepaid Assets | - | - | - | $10,351,000 |
| Debt | ||||
| Total Debt | $110,000 | $1,369,000 | $2,495,000 | $3,500,000 |
| Long Term Debt And Capital Lease Obligation | $0 | $110,000 | $1,369,000 | $2,495,000 |
| Current Debt And Capital Lease Obligation | $110,000 | $1,259,000 | $1,126,000 | $1,005,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $59,771,000 | $37,660,000 | $18,279,000 | $39,022,000 |
| Total Non Current Liabilities Net Minority Interest | $0 | $110,000 | $2,530,000 | $4,677,000 |
| Current Liabilities | $59,771,000 | $37,550,000 | $15,749,000 | $34,345,000 |
| Payables And Accrued Expenses | $40,948,000 | $26,926,000 | $9,515,000 | $27,719,000 |
| Payables | $24,628,000 | $12,528,000 | $5,815,000 | $14,672,000 |
| Accounts Payable | $24,628,000 | $12,528,000 | $5,815,000 | $14,672,000 |
| Non Current Deferred Liabilities | - | $0 | $1,161,000 | $2,182,000 |
| Current Deferred Liabilities | - | $0 | $1,392,000 | $2,818,000 |
| Equity | ||||
| Common Stock Equity | $878,136,000 | $445,450,000 | $69,669,000 | $76,106,000 |
| Total Equity Gross Minority Interest | $878,136,000 | $445,450,000 | $69,669,000 | $76,106,000 |
| Stockholders Equity | $878,136,000 | $445,450,000 | $69,669,000 | $76,106,000 |
| Gains Losses Not Affecting Retained Earnings | $563,000 | $654,000 | $0 | $-173,000 |
| Other Equity Adjustments | $563,000 | $654,000 | - | $-173,000 |
| Retained Earnings | $-1,140,008,000 | $-836,740,000 | $-653,921,000 | $-530,644,000 |
| Other | ||||
| Ordinary Shares Number | $25,195,092 | $19,422,358 | $8,791,877 | $3,292,163 |
| Share Issued | $25,195,092 | $19,422,358 | $8,791,877 | $3,292,163 |
| Tangible Book Value | $878,136,000 | $445,450,000 | $69,669,000 | $76,106,000 |
| Invested Capital | $878,136,000 | $445,450,000 | $69,669,000 | $76,106,000 |
| Working Capital | $551,140,000 | $366,822,000 | $69,131,000 | $76,495,000 |
| Capital Lease Obligations | $110,000 | $1,369,000 | $2,495,000 | $3,500,000 |
| Total Capitalization | $878,136,000 | $445,450,000 | $69,669,000 | $76,106,000 |
| Additional Paid In Capital | $2,017,566,000 | $1,281,522,000 | $723,577,000 | $606,918,000 |
| Capital Stock | $15,000 | $14,000 | $13,000 | $5,000 |
| Common Stock | $15,000 | $14,000 | $13,000 | $5,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $0 | $110,000 | $1,369,000 | $2,495,000 |
| Current Capital Lease Obligation | $110,000 | $1,259,000 | $1,126,000 | $1,005,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $18,713,000 | $9,365,000 | $3,716,000 | $2,803,000 |
| Current Accrued Expenses | $16,320,000 | $14,398,000 | $3,700,000 | $13,047,000 |
| Investments And Advances | $326,757,000 | $76,961,000 | $0 | - |
| Available For Sale Securities | $326,757,000 | $76,961,000 | - | - |
| Net PPE | $239,000 | $1,361,000 | $2,652,000 | $3,872,000 |
| Accumulated Depreciation | $-1,502,000 | $-1,363,000 | $-1,005,000 | $-572,000 |
| Gross PPE | $1,741,000 | $2,724,000 | $3,657,000 | $4,444,000 |
| Other Properties | $415,000 | $359,000 | $359,000 | $309,000 |
| Machinery Furniture Equipment | $1,234,000 | $1,234,000 | $1,234,000 | $1,234,000 |
| Buildings And Improvements | $92,000 | $1,131,000 | $2,064,000 | $2,901,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $242,002,000 | $177,195,000 | $0 | $38,874,000 |
| Non Current Deferred Revenue | - | $0 | $1,161,000 | $2,182,000 |
| Current Deferred Revenue | - | $0 | $1,392,000 | $2,818,000 |
Fetched: 2026-06-15
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-249,124,000 | $-131,757,000 | $-111,186,000 | $-185,487,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-249,068,000 | $-131,757,000 | $-111,136,000 | $-185,043,000 |
| Cash Flow From Continuing Operating Activities | $-249,068,000 | $-131,757,000 | $-111,136,000 | $-185,043,000 |
| Investing Activities | ||||
| Capital Expenditure | $-56,000 | - | $-50,000 | $-444,000 |
| Investing Cash Flow | $-311,148,000 | $-248,494,000 | $38,950,000 | $96,889,000 |
| Cash Flow From Continuing Investing Activities | $-311,148,000 | $-248,494,000 | $38,950,000 | $96,889,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $690,988,000 | $511,998,000 | $91,592,000 | $9,561,000 |
| Financing Cash Flow | $702,173,000 | $514,323,000 | $91,871,000 | $10,465,000 |
| Cash Flow From Continuing Financing Activities | $702,173,000 | $514,323,000 | $91,871,000 | $10,465,000 |
| Net Other Financing Charges | $-2,089,000 | $-308,000 | $-137,000 | $-522,000 |
| Net Common Stock Issuance | $690,988,000 | $511,998,000 | $91,592,000 | $9,561,000 |
| Common Stock Issuance | $690,988,000 | $511,998,000 | $91,592,000 | $9,561,000 |
| Repurchase Of Capital Stock | - | - | - | - |
| Net Preferred Stock Issuance | - | - | - | - |
| Preferred Stock Issuance | - | - | - | - |
| Other | ||||
| End Cash Position | $357,745,000 | $215,788,000 | $81,716,000 | $62,031,000 |
| Beginning Cash Position | $215,788,000 | $81,716,000 | $62,031,000 | $139,720,000 |
| Changes In Cash | $141,957,000 | $134,072,000 | $19,685,000 | $-77,689,000 |
| Proceeds From Stock Option Exercised | $13,274,000 | $2,633,000 | $416,000 | $1,426,000 |
| Net Investment Purchase And Sale | $-311,092,000 | $-248,494,000 | $39,000,000 | $97,333,000 |
| Sale Of Investment | $312,720,000 | $123,025,000 | $39,000,000 | $180,355,000 |
| Purchase Of Investment | $-623,812,000 | $-371,519,000 | $0 | $-83,022,000 |
| Net PPE Purchase And Sale | $-56,000 | $0 | $-50,000 | $-444,000 |
| Purchase Of PPE | $-56,000 | $0 | $-50,000 | $-444,000 |
| Change In Working Capital | $22,678,000 | $10,921,000 | $-14,032,000 | $-1,781,000 |
| Change In Other Current Liabilities | $-1,259,000 | $-1,126,000 | $-1,005,000 | $-811,000 |
| Change In Payables And Accrued Expense | $23,297,000 | $22,823,000 | $-17,352,000 | $-6,573,000 |
| Change In Accrued Expense | $11,200,000 | $16,110,000 | $-8,497,000 | $-10,465,000 |
| Change In Payable | $12,097,000 | $6,713,000 | $-8,855,000 | $3,892,000 |
| Change In Account Payable | $12,097,000 | $6,713,000 | $-8,855,000 | $3,892,000 |
| Change In Prepaid Assets | $640,000 | $-8,225,000 | $6,772,000 | $547,000 |
| Other Non Cash Items | $1,033,000 | $3,433,000 | $837,000 | $752,000 |
| Stock Based Compensation | $33,941,000 | $41,360,000 | $24,857,000 | $28,593,000 |
| Amortization Of Securities | $-3,592,000 | $-5,010,000 | $47,000 | $1,003,000 |
| Depreciation Amortization Depletion | $140,000 | $358,000 | $432,000 | $419,000 |
| Depreciation And Amortization | $140,000 | $358,000 | $432,000 | $419,000 |
| Depreciation | $140,000 | $358,000 | $432,000 | $419,000 |
| Net Income From Continuing Operations | $-303,268,000 | $-182,819,000 | $-123,277,000 | $-214,029,000 |
| Change In Other Working Capital | - | $-2,551,000 | $-2,447,000 | $5,056,000 |
| Preferred Stock Payments | - | - | - | - |
Fetched: 2026-06-15